

Sanofi Pasteur and the Alliance for Rabies Control enter into a Global Partnership

- Rabies: a neglected disease that kills one person every ten minutes¹ -

Lyon, France – October 2, 2009 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE : SNY), and the Alliance for Rabies Control (ARC) announced today their global partnership agreement to raise awareness about the importance of rabies prevention and control in the fight against this deadly infection. Rabies is a neglected disease that kills on average one person every ten minutes¹ worldwide. Sanofi Pasteur and ARC partner on rabies advocacy and educational awareness programs to help reduce human suffering from the disease.

“The fight against rabies requires a global and strong commitment from all health partners. The Alliance works with public and private partners to take action, share information and raise funds to prevent rabies.” said Deborah Briggs, Executive Director of the Alliance for Rabies Control. *“Sanofi Pasteur has always been a supporter of the ARC and we are pleased to bolster our relationships to break new ground against rabies.”*

“We are proud to reinforce our commitment to fight against rabies. Over 120 years after Louis Pasteur’s first human rabies immunization in 1885, rabies is still a public health threat in Asia and Africa, especially for children”, said Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur. *“Sanofi Pasteur is proud to help advance the fight against this fatal but vaccine-preventable disease.”*

World rabies day, an unprecedented opportunity to take action

Sanofi Pasteur is an official partner to the World Rabies Day led by the ARC. WRD is the only worldwide campaign dedicated to human and animal rabies prevention. For the first World Rabies Day in 2007, over 54 million people in 74 countries received educational messages in their own languages. Effective educational messages targeted at populations living at greatest risk of exposure to rabies have shown to help reduce mortality rate. Each year, on September 28, the Alliance and its partners work to extend the current scope and impact of World Rabies Day initiatives.

Rabies kills on average one person every 10 minutes (1)

Rabies is a neglected disease still causing a significant burden with approximately 55,000 estimated deaths worldwide annually, mostly in Asia and Africa. Children are particularly at high risk since they are less wary of unfamiliar dogs than adults and therefore are bitten more often, most commonly on the face or extremities. Rabies is an underestimated problem particularly in rural areas of endemic countries: 84% of deaths occur in rural areas in Asia and Africa.

Vaccination is the only effective prevention against rabies

The World Health Organization recommends that preventive vaccination programs should be promoted for children living in areas where canine rabies is endemic. It is also recommended for anyone at increased risk of exposure to the rabies virus such as laboratory staff, veterinarians and animal handlers, as well as travelers to areas with a high risk of rabies. Post-exposure prophylaxis for

severe bites requires both active immunization, with rabies vaccine, and passive immunization in the form of rabies immunoglobulins (RIG). In the last 20 years, over 20 million people in 100 countries have been treated with Sanofi Pasteur's rabies products (vaccines and rabies immunoglobulins).

Rabies vaccination by Louis Pasteur was an important step in vaccine history when, in 1885, Joseph Meister, who had been bitten by a rabid dog, was protected from contracting the disease by successive inoculations of Pasteur's rabies vaccine over a 10-day period.

About rabies

Rabies is an acute viral encephalitis transmitted from animal to animal or from animal to human by exposure to contaminated saliva. Virus in saliva attaches to peripheral nerve endings and progresses to the brain. All mammalian species are believed to be susceptible. Dogs are a major reservoir of human rabies. They are responsible for most of the reported rabid animal bites worldwide.

About the Alliance for Rabies Control

The Alliance for Rabies Control is the foremost non profit organization dedicated to eliminating rabies throughout the world. The mission of the Alliance is to promote rabies awareness and control. The organization contributes to support rabies control programs and educational initiatives.

The Alliance for Rabies Control was established to bring together public and private expertise in the field of rabies, including medical, veterinary, wildlife and animal welfare agencies, to utilize a 'one medicine' approach to establish rabies prevention programs. The Alliance coordinates the World Rabies Day campaign and works alongside its partner institutions and organizations. (www.rabiescontrol.net)

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2008, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

References:

(1) WHO Rabies Fact Sheet N°99 Revised September 2006 available at <http://www.who.int/mediacentre/factsheets/fs099/en/>

Media Contacts

Global Media Relations

Pascal Barollier
T. +33-(0)4-37-37-50-38
pascal.barollier@sanofipasteur.com
www.sanofipasteur.com

US Media Relations

Len Lavenda
T. +1-570-839-4446
len.lavenda@sanofipasteur.com
www.sanofipasteur.us